4117.TWO General Biologicals Corporation
- Market cap
- TWD 616M
- P/E
- 1.0x
- P/B
- 0.52x
- ROE
- 53.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is 4117.TWO undervalued?
Graham numberThe Graham number of General Biologicals Corporation cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
General Biologicals Corporation fundamental analysis
No fundamental analysis for General Biologicals Corporation yet.
General Biologicals Corporation stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About General Biologicals Corporation
General Biologicals Corporation engages in the research, development, manufacture, and sales of in-vitro diagnostics in Taiwan and internationally. The company offers ELISA and chemiluminescence immunoassay, molecular and cell diagnostic, and point-of-care testing services. It also provides Oncology & Liquid Biopsy; blood safety and screening services for hepatitis and HIV; contract development and manufacturing; IVD reagents and biomaterials. In addition, the company offers…
Full company profileGeneral Biologicals Corporation financial statements
General Biologicals Corporation annual financial statements (TWD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 240M | 476M | 552M | 370M | 265M | 252M | 216M |
| Gross Profit | 127M | 251M | 282M | 172M | 62.7M | 7.54M | 59.6M |
| Operating Income | -34.5M | 43.4M | 43.8M | -40.9M | -170M | -213M | -218M |
| EBITDA | -14.9M | 85.6M | 85.3M | 7.99M | -139M | -171M | 604M |
| Net Income | -39.0M | 62.2M | 44.1M | -53.2M | -199M | -221M | 466M |
| EPS | -0.99 | 1.18 | 0.74 | -0.89 | -3.32 | -3.69 | 6.58 |
| Balance Sheet | |||||||
| Total Assets | 281M | 833M | 1.26B | 1.55B | 2.54B | 3.41B | 4.87B |
| Total Liabilities | 209M | 146M | 530M | 858M | 2.04B | 3.12B | 4.00B |
| Shareholders' Equity | 71.9M | 685M | 732M | 691M | 495M | 285M | 871M |
| Cash & Short-term Investments | 31.6M | 476M | 370M | 351M | 217M | 252M | 243M |
| Total Debt | 118M | 69.2M | 454M | 470M | 550M | 2.31B | - |
| Cash Flow | |||||||
| Operating Cash Flow | -1.75M | 46.7M | 39.0M | 225M | 226M | -116M | -127M |
| Capital Expenditure | 1.15M | 25.9M | 125M | 249M | 425M | 1.52B | 176M |
| Free Cash Flow | -2.90M | 20.8M | -85.9M | -23.6M | -199M | -1.64B | -303M |
| Ratios | |||||||
| ROE | -54.3% | 9.1% | 6.0% | -7.7% | -40.2% | -77.6% | 53.5% |
| ROA | -13.9% | 7.5% | 3.5% | -3.4% | -7.8% | -6.5% | 9.6% |
| Net Profit Margin | -16.3% | 13.1% | 8.0% | -14.4% | -75.1% | -87.7% | 215.9% |
| Debt to Equity | 1.64x | 0.10x | 0.62x | 0.68x | 1.11x | 8.12x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
General Biologicals Corporation dividends
General Biologicals Corporation has not paid dividends in the last 7 fiscal years.
Who owns General Biologicals Corporation
Ownership data of General Biologicals Corporation is not available yet.
General Biologicals Corporation company profile
- Company name
- General Biologicals Corporation
- Ticker
- 4117.TWO
- ISIN
- TW0004117007
- Exchange
- Taiwan OTC Exchange
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Fiscal year end
- December
- Address
- No. 6, Innovation First Road, Hsinchu City, Taiwan, 300092
- Phone
- 886 3 577 9221
- Website
- gbc.com.tw
About General Biologicals Corporation
General Biologicals Corporation engages in the research, development, manufacture, and sales of in-vitro diagnostics in Taiwan and internationally. The company offers ELISA and chemiluminescence immunoassay, molecular and cell diagnostic, and point-of-care testing services. It also provides Oncology & Liquid Biopsy; blood safety and screening services for hepatitis and HIV; contract development and manufacturing; IVD reagents and biomaterials. In addition, the company offers various oral care, skincare, and related health products under the oh care brand. It serves its diagnostic and testing services through clinics and laboratories. General Biologicals Corporation was founded in 1984 and is headquartered in Hsinchu City, Taiwan.
General Biologicals Corporation management
3- Mr. Frank Lin M.B.A.President & Director
- Dr. C.M. LingFounder
- Ming Shan LiuDeputy General Manager of Sales Marketing and Director